貨號(hào)：GS40522

Ozanezumab (also known as GSK?1223249) is an investigational, humanized monoclonal antibody that targets neurite outgrowth inhibitor (Nogo?A), a protein primarily expressed in the central nervous system (CNS) that inhibits axonal growth and plasticity. By binding to Nogo?A, ozanezumab aims to neutralize its inhibitory activity, thereby promoting axonal regeneration, sprouting, and functional recovery after neurological injury. It was developed as a neurorestorative therapy for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), with the goal of slowing disease progression by enhancing neural repair. However, clinical trials in ALS did not demonstrate significant efficacy, and its development has been discontinued.